These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12037787)

  • 1. Preliminary results: outcome of liver transplantation for hepatitis B virus varies by hepatitis B virus genotype.
    Devarbhavi HC; Cohen AJ; Patel R; Wiesner RH; Dickson RC; Ishitani MB
    Liver Transpl; 2002 Jun; 8(6):550-5. PubMed ID: 12037787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.
    Han SH; Ofman J; Holt C; King K; Kunder G; Chen P; Dawson S; Goldstein L; Yersiz H; Farmer DG; Ghobrial RM; Busuttil RW; Martin P
    Liver Transpl; 2000 Nov; 6(6):741-8. PubMed ID: 11084061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation.
    Gane EJ; Angus PW; Strasser S; Crawford DH; Ring J; Jeffrey GP; McCaughan GW;
    Gastroenterology; 2007 Mar; 132(3):931-7. PubMed ID: 17383422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B virus genotype A and D and clinical outcomes of liver transplantation for HBV-related disease.
    Girlanda R; Mohsen AH; Smith H; Sablon E; Yuen MF; O'Grady J; Muiesan P; Rela M; Heaton N; Norris S
    Liver Transpl; 2004 Jan; 10(1):58-64. PubMed ID: 14755779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation.
    Faria LC; Gigou M; Roque-Afonso AM; Sebagh M; Roche B; Fallot G; Ferrari TC; Guettier C; Dussaix E; Castaing D; Brechot C; Samuel D
    Gastroenterology; 2008 Jun; 134(7):1890-9; quiz 2155. PubMed ID: 18424269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin.
    McCaughan GW; Spencer J; Koorey D; Bowden S; Bartholomeusz A; Littlejohn M; Verran D; Chui AK; Sheil AG; Jones RM; Locarnini SA; Angus PW
    Liver Transpl Surg; 1999 Nov; 5(6):512-9. PubMed ID: 10545540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin.
    Markowitz JS; Martin P; Conrad AJ; Markmann JF; Seu P; Yersiz H; Goss JA; Schmidt P; Pakrasi A; Artinian L; Murray NG; Imagawa DK; Holt C; Goldstein LI; Stribling R; Busuttil RW
    Hepatology; 1998 Aug; 28(2):585-9. PubMed ID: 9696028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination prophylaxis with Hepatitis B immunoglobulin and lamivudine after liver transplantation minimizes HBV recurrence rates unless evolution of pretransplant lamivudine resistance.
    Seehofer D; Rayes N; Steinmüller T; Müller AR; Jonas S; Settmacher U; Neuhaus R; Berg T; Neuhaus P
    Z Gastroenterol; 2002 Sep; 40(9):795-9. PubMed ID: 12215948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation.
    Karasu Z; Ozacar T; Akyildiz M; Demirbas T; Arikan C; Kobat A; Akarca U; Ersoz G; Gunsar F; Batur Y; Kilic M; Tokat Y
    Antivir Ther; 2004 Dec; 9(6):921-7. PubMed ID: 15651751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation.
    Dodson SF; de Vera ME; Bonham CA; Geller DA; Rakela J; Fung JJ
    Liver Transpl; 2000 Jul; 6(4):434-9. PubMed ID: 10915164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis.
    Akyildiz M; Karasu Z; Zeytunlu M; Aydin U; Ozacar T; Kilic M
    J Gastroenterol Hepatol; 2007 Dec; 22(12):2130-4. PubMed ID: 18031370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of hepatitis B recurrence after liver transplantation using lamivudine and hepatitis B immune globulin.
    Ołdakowska-Jedynak U; Paczek L; Foroncewicz B; Mucha K; Nyckowski P; Zieniewicz K; Ziarkiewicz-Wróblewska B; Ziółkowski J; Pilecki T; Patkowski W; Górnicka B; Paczkowska A; Krawczyk M
    Ann Transplant; 2007; 12(3):28-32. PubMed ID: 18290567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotype prevalence, viral load and outcome of hepatitis B virus precore mutant infection in stable patients and in patients after liver transplantation.
    Ben-Ari Z; Ashur Y; Daudi N; Shmilovitz-Wiess H; Brown M; Sulkes J; Klein A; Mor E; Tur-Kaspa R; Shouval D
    Clin Transplant; 2004 Aug; 18(4):415-22. PubMed ID: 15233819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A study on mutations of the overlapping hepatitis B virus surface and polymerase gene in patients with HBV reinfection after liver transplantations].
    Song HL; Shen ZY; Wang J; Zheng WP; Wang ZL
    Zhonghua Gan Zang Bing Za Zhi; 2008 Apr; 16(4):265-9. PubMed ID: 18423147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of hepatitis B recurrence after living donor liver transplantation: primary high-dose hepatitis B immunoglobulin monotherapy and rescue antiviral therapy.
    Hwang S; Lee SG; Ahn CS; Kim KH; Moon DB; Ha TY; Song GW; Jung DH; Park JI; Ryu JH; Lee HJ; Suh DJ; Lim YS
    Liver Transpl; 2008 Jun; 14(6):770-8. PubMed ID: 18508369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis.
    Roche B; Feray C; Gigou M; Roque-Afonso AM; Arulnaden JL; Delvart V; Dussaix E; Guettier C; Bismuth H; Samuel D
    Hepatology; 2003 Jul; 38(1):86-95. PubMed ID: 12829990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intramuscular hepatitis B immunoglobulin (HBIG) and nucleosides for prevention of recurrent hepatitis B following liver transplantation: comparison with other HBIG regimens.
    Anderson RD; Chinnakotla S; Guo L; Perrillo RP; Klintmalm GB; Davis GL
    Clin Transplant; 2007; 21(4):510-7. PubMed ID: 17645711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in the hepatitis B virus precore/core gene and core promoter in patients with severe recurrent disease following liver transplantation.
    McMillan JS; Bowden DS; Angus PW; McCaughan GW; Locarnini SA
    Hepatology; 1996 Dec; 24(6):1371-8. PubMed ID: 8938164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence.
    Marzano A; Gaia S; Ghisetti V; Carenzi S; Premoli A; Debernardi-Venon W; Alessandria C; Franchello A; Salizzoni M; Rizzetto M
    Liver Transpl; 2005 Apr; 11(4):402-9. PubMed ID: 15776431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral persistence after liver transplantation for hepatitis B virus: a cross-sectional study.
    Freshwater DA; Dudley T; Cane P; Mutimer DJ
    Transplantation; 2008 Apr; 85(8):1105-11. PubMed ID: 18431229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.